Company Introduction

AnHorn Medicines is a novel drug discovery company with a strong pipeline, offering therapies that Target and Degrade disease-causing proteins. Our mission is to develop new class of BIGPRO® (Bi-functional liGand induced PROteolysis) drugs under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.
 
安宏生醫AnHorn Medicines 應用AI人工智慧進行新型藥物開發，打造全新蛋白質降解藥物 BIGPRO®，治療眾多危及生命的疾病。安宏生醫已在癌症、神經退化性疾病及老年疾病等拓展多項研發產品線，並積極與世界級藥物開發領先公司洽談策略合作，開展BIGPRO® 蛋白質降解藥物的後期研究。
 
安宏生醫裡的每位夥伴都對創新的科學發展懷抱熱情及好奇心，我們相信安宏生醫的使命對推展科學發展及藥物創新的執著能夠大幅改善病人的生活品質。

Brief description of main products or services 

AnHorn Medicines focus on novel therapies for cancer, neurodegeneration, and aging diseases by applying AnHorn’s proprietary AIMCADD® platform. We are turning innovation into new therapeutics – new opportunities to target difficult-to-treat and drug resisting diseases.

AnHorn’s Drug Development Strategy:
．Focuses on discovering BIGPRO® new drugs
．Develops novel E3 ligase and its ligand
．Expands unexplored therapeutic opportunity in undruggable targets
．Establishes a multilayer patent protection framework for projects